Article Details
Retrieved on: 2024-05-21 16:57:26
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article outlines AstraZeneca's ambitious revenue and sustainability goals under Pascal Soriot's leadership, focusing on expanding its oncology and rare disease portfolios. The mention of various groundbreaking medical developments highlights AstraZeneca's efforts in immunology and medical research within Södertälje Municipality. The term 'franchise' ties into the diverse drug pipeline, including bispecific monoclonal antibodies and antibody-drug conjugates, aimed at generating significant sales.
Article found on: pharmaphorum.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here